@clellandlab.bsky.social
The Clelland lab is devoted to curing neurodegenerative diseases. We are working to create therapies for patients with fatal FTD, ALS, AD, PD and other neurologic diseases
This study shows GRN regulates phagocytic receptors MERTK and AXL in microglia, impacting FTD pathology. MERTK drops in CSF after symptom onset in GRN, MAPT, and C9orf72 cases, making it a promising biomarker. Thanks to all contributors who made this discovery possible.
July 9, 2025 at 5:22 PM
This study shows GRN regulates phagocytic receptors MERTK and AXL in microglia, impacting FTD pathology. MERTK drops in CSF after symptom onset in GRN, MAPT, and C9orf72 cases, making it a promising biomarker. Thanks to all contributors who made this discovery possible.
And having a genetic or rare fatal disease is not lucky
January 24, 2025 at 5:43 AM
And having a genetic or rare fatal disease is not lucky
As an MS specialist I’m not surprised you’re not seeing familial FTD cases. There are 60k people in the US with FTD and that’s likely an underestimate given how often it is misdiagnosed. 1.8M people worldwide. 10% are MAPT mutation carriers. Actually not so few.
January 24, 2025 at 5:42 AM
As an MS specialist I’m not surprised you’re not seeing familial FTD cases. There are 60k people in the US with FTD and that’s likely an underestimate given how often it is misdiagnosed. 1.8M people worldwide. 10% are MAPT mutation carriers. Actually not so few.